Synthesis and in vitro evaluation of [carbonyl-¹¹C]estramustine and [carbonyl-¹¹C]estramustine phosphateLIDSTRÖM, P; BONASERA, T. A; MARQUEZ-M, M et al.Steroids. 1998, Vol 63, Num 4, pp 228-234, issn 0039-128XArticle

Induction of aneuploidy by the antineoplastic drug estramustine in human lymphocytesMIGLIORE, L; COCCHI, L; SCARPATO, R et al.Mutation research. Genetic toxicology and environmental mutagenesis. 1998, Vol 412, Num 1, pp 33-40, issn 1383-5718Article

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancerNOGUCHI, Masanori; KAKUMA, Tatsuyuki; SHICHIJO, Shigeki et al.Cancer immunology and immunotherapy. 2010, Vol 59, Num 7, pp 1001-1009, issn 0340-7004, 9 p.Article

Combination Chemotherapy with Docetaxel, Vinorelbine and Estramustine Phosphate in Metastatic Androgen-resistant Prostate Cancer : A Single Institution ExperiencePECTASIDES, Dimitrios; PECTASIDES, Eirini; G, Panagiotis et al.Anticancer research. 2009, Vol 29, Num 2, pp 769-775, issn 0250-7005, 7 p.Article

Prognostic and Predictive Factors in Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel and Estramustine : A Single Institution Experience. CommentariesBAMIAS, Aristotle; BOZAS, George; DIMOPOULOS, Meletios A et al.European urology. 2008, Vol 53, Num 2, pp 323-332, issn 0302-2838, 10 p.Article

Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate CancerMACHIELS, Jean-Pascal; MAZZEO, Filomena; VERHOEVEN, Didier et al.Journal of clinical oncology. 2008, Vol 26, Num 32, pp 5261-5268, issn 0732-183X, 8 p.Article

Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24⁺ HRPC patientsNOGUCHI, Masanori; ITOH, Kyogo; YAO, Akihisa et al.The Prostate. 2005, Vol 63, Num 1, pp 1-12, issn 0270-4137, 12 p.Article

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancerGALSKY, Matthew D; SMALL, Eric J; KELLY, W. Kevin et al.Journal of clinical oncology. 2005, Vol 23, Num 7, pp 1439-1446, issn 0732-183X, 8 p.Article

The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphateSUZUKI, Motofumi; MOHAMMED RAFIQUL ISLAM MAMUN; OHTA, Nobutaka et al.European urology. 2005, Vol 48, Num 5, pp 752-759, issn 0302-2838, 8 p.Article

The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer : A phase II feasibility study conducted by the Hellenic cooperative oncology groupSAMELIS, Georgios Fotios; KALOFONOS, Haralambos; ADAMOU, Adamos et al.Urology (Ridgewood, NJ). 2005, Vol 66, Num 2, pp 382-385, issn 0090-4295, 4 p.Article

Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer : A single-center experienceBOEHMER, Angela; ANASTASIADIS, Aristotelis G; FEYERABEND, Susan et al.Anticancer research. 2005, Vol 25, Num 6C, pp 4481-4486, issn 0250-7005, 6 p.Article

Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphomaBORGHAEI, Hossein; MILLENSON, Michael; SCHILDER, Russell et al.Cancer. 2004, Vol 101, Num 9, pp 2034-2041, issn 0008-543X, 8 p.Article

Synthesis of estromustine, estramustine and estramustine phosphate labelled with deuteriumGIRIBONE, Danilo; FONTANA, Erminia.Journal of labelled compounds & radiopharmaceuticals. 2004, Vol 47, Num 2, pp 161-165, issn 0362-4803, 5 p.Article

Dose escalation study of intravenous estramustine phosphate in combination with paclitaxel and carboplatin in Patients with advanced prostate cancerKELLY, William Kevin; ZHU, Andrew X; PELLIZZONI, Cinzia et al.Clinical cancer research. 2003, Vol 9, Num 6, pp 2098-2107, issn 1078-0432, 10 p.Article

Actualités thérapeutiques sur la prostate = Update in the treatment of prostate cancerPONZIO-PRION, A.La Lettre du cancérologue (Boulogne). 2003, Vol FEV, pp 2-4, issn 1165-113X, 3 p., NSArticle

Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinomaSOLIT, David B; MORRIS, Michael; SLOVIN, Susan et al.Cancer. 2003, Vol 98, Num 9, pp 1842-1848, issn 0008-543X, 7 p.Article

Hypertriglyceridemia and pancreatitis associated with estramustine phosphateOLSON, Eric L; WHANG, Young E.American journal of clinical oncology. 2002, Vol 25, Num 4, pp 342-343, issn 0277-3732Article

An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancerVAISHAMPAYAN, Ulka; FONTANA, Joseph; WEI DU et al.Urology (Ridgewood, NJ). 2002, Vol 60, Num 6, pp 1050-1054, issn 0090-4295, 5 p.Article

A phase II trial of estramustine and etoposide in hormone refractory prostate cancer : A Southwest Oncology Grouptrial (SWOG 9407)PIENTA, Kenneth J; FISHER, Emily I; EISENBERGER, Mario A et al.The Prostate. 2001, Vol 46, Num 4, pp 257-261, issn 0270-4137Article

Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancerHAAS, Naomi; ROTH, Bruce; GILLON, Thomas et al.Urology (Ridgewood, NJ). 2001, Vol 58, Num 1, pp 59-64, issn 0090-4295Article

Induction of apoptosis by estramustine phosphate mediated by phosphorylation of bcl-2YOSHIDA, Daizo; NOHA, Masahiro; WATANABE, Kunihiro et al.Journal of neuro-oncology. 2001, Vol 54, Num 1, pp 23-29, issn 0167-594XArticle

Treatment options in hormone-refractory prostate cancer: Current and future approachesHARRIS, Katherine A; REESE, David M.Drugs (Basel). 2001, Vol 61, Num 15, pp 2177-2192, issn 0012-6667Article

Estramustine phosphate withdrawal syndrome with dramatic pain reliefSHIBATA, Y; MORITA, T; KASHIWAGI, B et al.The Journal of urology. 1999, Vol 162, Num 3, issn 0022-5347, p. 805, 1Article

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer : A Hoosier oncology group and fox chase network phase III trialHUDES, G; EINHORN, L; MONACO, F et al.Journal of clinical oncology. 1999, Vol 17, Num 10, pp 3160-3166, issn 0732-183XArticle

Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancerKREIS, W; BUDMAN, D.Seminars in oncology. 1999, Vol 26, Num 5, pp 34-38, issn 0093-7754, SUP17Article